Connect with others who understand.

sign up log in
Resources
About MyMyelomaTeam

Connect with others who understand.

sign up log in
Resources
About MyMyelomaTeam

Stage 2 Multiple Myeloma Prognosis: Fear, Hope, and Understanding Survival Rates

Posted on March 23, 2022
Medically reviewed by
Mark Levin, M.D.
Article written by
Jennifer Berger, Ph.D.

Multiple myeloma is a type of blood cancer that affects plasma cells. Plasma cells are white blood cells that produce antibodies to fight infections. In multiple myeloma, cancerous plasma cells (called multiple myeloma cells) crowd out normal cells in the bone marrow, resulting in loss of function of the normal bone marrow cells. Instead of producing helpful antibodies as normal plasma cells do, myeloma cells produce abnormal antibodies that can build up in tissues and be harmful.

Doctors assign each case of multiple myeloma a stage. The stages of multiple myeloma tell you how advanced the cancer is and how much it has spread within the body. Doctors use staging information to guide treatment decisions and to estimate a person’s outlook.

What Is Stage 2 Multiple Myeloma?

Cancers are staged according to many criteria specific to each type of cancer. Oncologists (doctors who specialize in diagnosing and treating cancer) use blood tests to determine the stage of a person’s multiple myeloma.

There are two staging systems for multiple myeloma: the Durie-Salmon Staging System and the International Staging System (ISS). The ISS replaced the Durie-Salmon Staging System in 2005. The ISS was revised in 2015 — called the Revised ISS (R-ISS) — to include additional factors affecting the severity of multiple myeloma.

Revised International Staging System

In the R-ISS, there are three stages of multiple myeloma. The higher the number, the later the stages, which indicates more severe disease. In other words, stage 2 multiple myeloma is more advanced and more severe than stage 1.

The R-ISS takes into account levels of three proteins found in the blood: albumin, beta-2 microglobulin, and lactate dehydrogenase (LDH). Lower levels of albumin and higher levels of beta-2 microglobulin and LDH indicate that myeloma is becoming more advanced. The R-ISS is also based on cytogenetics — gene changes found within the myeloma cells.

Stage 2 Multiple Myeloma

The R-ISS indicates stage 2 multiple myeloma when clinical test results are between those of stage 1 and stage 3. In other words, stage 2 is indicated when a person exhibits some of the factors characteristic of stage 1 and of stage 3.

Stage 1 multiple myeloma is indicated when the person exhibits all of the following factors:

  • Beta-2 microglobulin level less than 3.5 milligrams per liter
  • Albumin level equal to or greater than 3.5 grams per deciliter
  • Normal LDH levels
  • Cancer genetics that are not considered high risk

The R-ISS indicates stage 3 multiple myeloma when the person exhibits beta-2 microglobulin level of 5.5 milligrams per liter or higher, along with high-risk cancer genetics and/or high LDH levels.

If you have any questions about your multiple myeloma stage, ask your doctor to explain what your test results mean and how your stage is measured. You can also ask how your myeloma stage affects treatment options and outlook.

Signs and Symptoms of Stage 2 Multiple Myeloma

Sometimes, a doctor will detect signs of myeloma on blood tests and make a diagnosis before noticeable symptoms appear. As myeloma advances in stage, it may be more likely to lead to signs and symptoms of myeloma, including:

  • Bone pain
  • Extreme tiredness
  • High levels of calcium in the blood
  • Anemia (low levels of red blood cells)
  • Thrombocytopenia (low platelet counts)
  • Decreased kidney function
  • Bone lesions (abnormalities or bone damage)
  • Frequent infections

If you are experiencing bone pain or any other symptoms of multiple myeloma, talk to your doctor.

Treatments for Stage 2 Multiple Myeloma

Most forms of active multiple myeloma, including stage 2, are treated in a similar way. People with myeloma generally receive a combination of different drugs, including chemotherapies, biological therapy, or monoclonal antibodies. Other options may include:

People with stage 2 myeloma may need to use more aggressive treatment options than those with stage 1 disease.

Many people with multiple myeloma also use supportive treatments. These are therapies that don’t aim to kill cancer cells. Rather, supportive treatments help improve myeloma signs and symptoms. For example, people with stage 2 myeloma may use bisphosphonate drugs to treat bone pain and strengthen bones.

Outlook and Survival for Stage 2 Multiple Myeloma

Between the years 2011 and 2017, the overall five-year survival rate for multiple myeloma was 55.6 percent. That means that 55.6 percent of people with multiple myeloma were alive five years after their diagnosis. Cancer treatments are improving, so today’s outlook for multiple myeloma is likely better than what’s reported.

Survival statistics vary among people with different R-ISS stages, as well:

  • About 82 percent of people with stage 1 disease live for five years or more after being diagnosed.
  • Approximately 62 percent of people with stage 2 disease live at least five years after diagnosis.
  • About 40 percent of people with stage 3 disease live for five years or more.

The median length of survival after diagnosis with multiple myeloma is:

  • 62 months for stage 1
  • 44 months for stage 2
  • 29 months for stage 3

Generally, a person with a later stage of cancer will have a poorer prognosis than someone with an earlier stage. Because stage 2 is a combination of factors from stage 1 and stage 3 multiple myeloma, predicting outlook and survival is often more complicated than referring to stage alone.

If a person with stage 2 multiple myeloma has three factors from the R-ISS that can be considered stage 3 and only one factor that can be considered stage 1, that person will likely have a poorer prognosis than someone who only has one factor characteristic of stage 3, for example.

In addition to the characteristics used in the R-ISS, several other risk factors contribute to the prognosis of stage 2 multiple myeloma, including:

  • Age
  • Overall health
  • Kidney function
  • Bone damage

The younger a person is when diagnosed with multiple myeloma, the longer their life expectancy will be. People with multiple myeloma who have good overall health generally have better prognoses.

Kidney function can be impaired by the abnormal proteins made by the cancerous plasma cells and by high calcium levels. People living with multiple myeloma who have abnormally functioning kidneys survive an average of 20 months compared to 40 months in people with healthy kidneys. Bone disease may also be a sign of advancing multiple myeloma and a poorer outlook for the person living with the disease.

As new treatments are approved and applied, the outlook and survival for people living with multiple myeloma should continue to improve. Ongoing cancer research, including many clinical trials, is underway to develop new cancer treatments for multiple myeloma.

Talk With Others Who Understand

MyMyelomaTeam is the social network for people with myeloma and their loved ones. On MyMyelomaTeam, more than 14,000 members come together to ask questions, give advice, and share their stories with others who understand life with myeloma.

Are you living with stage 2 multiple myeloma? Share your experience in the comments below, or start a conversation by posting on MyMyelomaTeam.

All updates must be accompanied by text or a picture.
Mark Levin, M.D. is a hematology and oncology specialist with over 37 years of experience in internal medicine. Review provided by VeriMed Healthcare Network. Learn more about him here.
Jennifer Berger, Ph.D. is a microbiologist at the University of Colorado Anschutz Medical Center. Learn more about her here.

Related articles

People over 50 and those who are immunocompromised are now eligible to get a second COVID-19...

What People With Myeloma Should Know About Getting a Second COVID-19 Booster Shot

People over 50 and those who are immunocompromised are now eligible to get a second COVID-19...
Myeloma is a type of cancer that affects plasma cells.

How Does Myeloma Spread Through the Body?

Myeloma is a type of cancer that affects plasma cells.
Many treatments can help kill myeloma cells and reduce myeloma symptoms. These therapies can...

Can Multiple Myeloma Be Cured?

Many treatments can help kill myeloma cells and reduce myeloma symptoms. These therapies can...
Extramedullary plasmacytoma (EMP) is a rare cancer that forms from plasma cells (a type of white...

Extramedullary Plasmacytoma: Your Guide

Extramedullary plasmacytoma (EMP) is a rare cancer that forms from plasma cells (a type of white...
Multiple myeloma is a blood cancer that occurs when one type of white blood cell called a...

Multiple Myeloma Types and Related Conditions

Multiple myeloma is a blood cancer that occurs when one type of white blood cell called a...
Multiple myeloma is a type of blood cancer that occurs when lymphocytes (white blood cells)...

Multiple Myeloma – An Overview

Multiple myeloma is a type of blood cancer that occurs when lymphocytes (white blood cells)...

Recent articles

Multiple myeloma can affect your quality of life, interfering with your work, social life, and...

5 Causes of Multiple Myeloma Fatigue and 4 Ways To Manage It

Multiple myeloma can affect your quality of life, interfering with your work, social life, and...
The U.S. Food and Drug Administration (FDA) has approved updated boosters for messenger RNA...

New COVID-19 Vaccine Boosters for Omicron: What To Know if You Have Myeloma

The U.S. Food and Drug Administration (FDA) has approved updated boosters for messenger RNA...
If you’ve received a myeloma diagnosis, you may be wondering how alcohol consumption can affect your symptoms and disease progression.

Myeloma and Alcohol: 4 Things To Know

If you’ve received a myeloma diagnosis, you may be wondering how alcohol consumption can affect your symptoms and disease progression.
Monoclonal gammopathy of undetermined significance (MGUS) is a noncancerous condition in which...

Can You Prevent MGUS From Progressing?

Monoclonal gammopathy of undetermined significance (MGUS) is a noncancerous condition in which...
Working while undergoing treatment for multiple myeloma is a personal decision with several...

Working With Multiple Myeloma

Working while undergoing treatment for multiple myeloma is a personal decision with several...
Thanks to years of cancer research and public-health messaging, most people understand that...

Smoking and Multiple Myeloma

Thanks to years of cancer research and public-health messaging, most people understand that...
MyMyelomaTeam My myeloma Team

Thank you for subscribing!

Become a member to get even more:

sign up for free

close